The influenza vaccine in Moderna shows positive experimental results, and the paving method

accident He said on the experimental Monday The influenza vaccine based on us It produced a stronger immune response than a snapshot currently available in a late stage experience, which leads to a route to the front of the product and Covid Jab Covid Jox.

Moderna in May I voluntarily pulled a request In an effort to obtain approval of a set of shots targeting Covid-19 and influenza, she said it has plans to re-present them with effectiveness data from the third stage experience on an independent influenza vaccine. This decision came after discussions with the Food and Drug Administration, which is struggling with tremendous reform under the Minister of Health and Humanitarian Services Robert Kennedy Junior, who is skeptical of the vaccine.

Through new data, the company plans to re -submit a plural vaccine request and a file to agree to an independent influenza later this year, said Stephen Hug, head of the company’s research and development, said in an interview.

Hoge said that if the organizers agreed to the influenza vaccine, the company can offer the group shot. He added that Moderna expects approvals for both shots next year awaiting reviews.

ModeRa shares increased more than 5 % in the two market pre -market.

Hoji said that the JAB mixture simplifies the vaccination, which will help the “health care system” by reducing the work burdens of doctors and nurses, reducing costs and improving absorption between patients.

It seems that the company so far is the candidate in the race against Vizar and Novavax To bring a snapshot mixture to the market. While Moderna does not have specific revenue expectations for its individual products, Hoge is the Covid, Flu and Virus Syncytial virus is billions of dollars in markets.

“It is clear that we hope that our products will allow us to win our fair share,” he said.

The third stage followed the experience of more than 40,000 adults between the ages of 50 years and over, and who were randomly appointed to receive one dose of Moderna, called MRNA-1010, or a standard competitor vaccine. Moderna’s shot was 26.6 % more effective than the other vaccine in the total population.

JAB -1010 JAB -1010 showed a strong effectiveness of each of the main influenza breeds in the shot, including A/H1N1, A/H3N2 and B/Victoria. Moderna said that the use of the vaccine was consistent with different age groups, people with different risk factors and previous vaccination against influenza.

In adults between the ages of 65 years and over, the shot was 27.4 % more effective than the standard influenza vaccine.

“The results of the event are” a milestone in our efforts to reduce the influenza burden in the elderly. ” “The intensity of the influenza season this past emphasizes the need for more effective vaccines.”

Modern martyrdom has been done Data One of the centers of control and prevention control that shows that the seasonal hospitals related to influenza and outpatient visits reached the highest level in 2024 to 2025 of the virus. More than 600,000 Americans It was transferred to the hospital due to the disease associated with influenza last year, according to the Center for Disease Control.

Safety data in a -1010 -1010 vaccine was consistent with the previous results from studying another third -class stage on the shot.

Midena shares decreased by more than 30 % for the year that enters Monday, and nourishes it in large part of a series of moves by the Trump administration to change the policy policy and undermine vaccination. Administration in May Eliminate A grant for Moderna for the late development of its influenza vaccine for human beings.

When asked about the unconfirmed organizational environment in the United States, Huj said that Moderna is closely involved with the FDA to understand what its requirements are and how to satisfy it.

“I think, regarding influenza, I think we have a completely clear way,” he said.